Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Ifosfamide

First Posted Date: 2010-04-13

Last Posted Date: 2012-03-20

Lead Sponsor: Grupo Espanol de Investigacion en Sarcomas

Target Recruit Count: 32

Registration Number: NCT01102608

Locations: 🇪🇸
Grupo Espanol de Investigación en Sarcomas, Barcelona, España, Spain

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Biological: Filgrastim
Drug: Ifosfamide
Procedure: Leukapheresis
Drug: Plerixafor
Biological: Rituximab

First Posted Date: 2010-04-01

Last Posted Date: 2018-01-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01097057

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Phase 2

Completed

Conditions: Untreated Childhood Rhabdomyosarcoma
Childhood Alveolar Rhabdomyosarcoma
Childhood Embryonal Rhabdomyosarcoma
Adult Rhabdomyosarcoma
Metastatic Childhood Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Biological: Cixutumumab
Biological: Dactinomycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Doxorubicin Hydrochloride
Drug: Ifosfamide
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Temozolomide
Drug: Vincristine Sulfate Liposome

First Posted Date: 2010-01-25

Last Posted Date: 2017-08-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 175

Registration Number: NCT01055314

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States

and more 136 locations

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Phase 3

Completed

Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: doxorubicin hydrochloride
Drug: liposomal vincristine sulfate
Drug: vinorelbine tartrate
Drug: etoposide phosphate
Drug: cyclophosphamide
Drug: prednisone
Biological: filgrastim
Drug: ifosfamide

First Posted Date: 2009-12-04

Last Posted Date: 2022-04-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 166

Registration Number: NCT01026220

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States

and more 174 locations

Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-09-10

Last Posted Date: 2013-08-26

Lead Sponsor: Cancer Research UK

Target Recruit Count: 150

Registration Number: NCT00974792

Locations: 🇬🇧
Nottingham City Hospital, Nottingham, England, United Kingdom

Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

First Posted Date: 2009-08-27

Last Posted Date: 2012-02-01

Lead Sponsor: IRCCS San Raffaele

Target Recruit Count: 21

Registration Number: NCT00967291

Locations: 🇮🇹
Istituto Scientifico H. San Raffaele, Milan, Italy

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Phase 2

Completed

Conditions: Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions: Drug: Bortezomib
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide

First Posted Date: 2009-08-27

Last Posted Date: 2020-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00967369

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Phase 1

Terminated

Conditions: Bone Cancer
Neoplasms
Solid Tumors
Neuroblastoma
Kidney Tumor

Interventions: Drug: Temozolomide
Drug: Vincristine
Drug: Ifosfamide
Drug: Irinotecan
Biological: Robatumumab
Drug: Doxorubicin
Drug: Etoposide
Drug: Cyclophosphamide

First Posted Date: 2009-08-17

Last Posted Date: 2018-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 4

Registration Number: NCT00960063

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 3

Conditions: Stage IA Uterine Sarcoma AJCC v7
Mixed Mesodermal (Mullerian) Tumor
Stage IA Ovarian Cancer AJCC v6 and v7
Stage IB Fallopian Tube Cancer AJCC v6 and v7
Stage IC Ovarian Cancer AJCC v6 and v7
Stage IIA Uterine Sarcoma AJCC v7
Stage IIC Fallopian Tube Cancer AJCC v6 and v7
Stage IIIA Ovarian Cancer AJCC v6 and v7
Stage IIIB Uterine Sarcoma AJCC v7
Stage IV Fallopian Tube Cancer AJCC v6 and v7

Interventions: Drug: Carboplatin
Drug: Ifosfamide
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2009-08-07

Last Posted Date: 2021-09-30

Lead Sponsor: GOG Foundation

Target Recruit Count: 637

Registration Number: NCT00954174

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 532 locations

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Phase 2

Completed

Conditions: Testicular Cancer

Interventions: Drug: Gemcitabine
Drug: Docetaxel
Drug: Mesna
Drug: Melphalan
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Procedure: Stem Cell Transplant

First Posted Date: 2009-07-10

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00936936

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy